[go: up one dir, main page]

MX2025008168A - Métodos de tratamiento de los síntomas del trastorno del espectro autista. - Google Patents

Métodos de tratamiento de los síntomas del trastorno del espectro autista.

Info

Publication number
MX2025008168A
MX2025008168A MX2025008168A MX2025008168A MX2025008168A MX 2025008168 A MX2025008168 A MX 2025008168A MX 2025008168 A MX2025008168 A MX 2025008168A MX 2025008168 A MX2025008168 A MX 2025008168A MX 2025008168 A MX2025008168 A MX 2025008168A
Authority
MX
Mexico
Prior art keywords
treating
methods
symptoms
autism spectrum
spectrum disorder
Prior art date
Application number
MX2025008168A
Other languages
English (en)
Inventor
James Lillie
Michael Wood
Original Assignee
Maplight Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maplight Therapeutics Inc filed Critical Maplight Therapeutics Inc
Publication of MX2025008168A publication Critical patent/MX2025008168A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

En la presente se proporcionan métodos de tratamiento de los síntomas asociados con el trastorno del espectro autista (TEA) mediante la administración de una cantidad terapéuticamente eficaz de un triptán.
MX2025008168A 2019-10-23 2022-04-22 Métodos de tratamiento de los síntomas del trastorno del espectro autista. MX2025008168A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962925023P 2019-10-23 2019-10-23
US202063011715P 2020-04-17 2020-04-17
PCT/US2020/057133 WO2021081376A1 (en) 2019-10-23 2020-10-23 Methods of treating the symptoms of autism spectrum disorder

Publications (1)

Publication Number Publication Date
MX2025008168A true MX2025008168A (es) 2025-08-01

Family

ID=75620321

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022004910A MX2022004910A (es) 2019-10-23 2020-10-23 Metodos de tratamiento de los sintomas del trastorno del espectro autista.
MX2025008168A MX2025008168A (es) 2019-10-23 2022-04-22 Métodos de tratamiento de los síntomas del trastorno del espectro autista.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2022004910A MX2022004910A (es) 2019-10-23 2020-10-23 Metodos de tratamiento de los sintomas del trastorno del espectro autista.

Country Status (14)

Country Link
US (1) US20220387396A1 (es)
EP (2) EP4681714A2 (es)
JP (1) JP7766026B2 (es)
KR (1) KR20220122602A (es)
CN (1) CN114901270A (es)
AU (1) AU2020370479A1 (es)
CA (1) CA3158781A1 (es)
DK (1) DK4048249T3 (es)
FI (1) FI4048249T3 (es)
HR (1) HRP20251489T1 (es)
IL (1) IL292367A (es)
MX (2) MX2022004910A (es)
PT (1) PT4048249T (es)
WO (1) WO2021081376A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4208161A1 (en) * 2020-10-16 2023-07-12 Purposeful, Ike Compositions and uses thereof
MX2023011240A (es) * 2021-03-25 2024-01-12 Maplight Therapeutics Inc Composiciones farmaceuticas que comprenden zolmitriptan.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236787B2 (en) * 2008-12-09 2012-08-07 Synthonics, Inc. Frequency modulated drug delivery (FMDD)
EP3145906B1 (en) * 2014-05-19 2023-10-04 Northeastern University Serotonin receptor-targeting compounds
WO2016138138A1 (en) * 2015-02-25 2016-09-01 The Regents Of The University Of California 5ht agonists for treating disorders
CN114470009A (zh) * 2015-05-22 2022-05-13 亚利桑那大学董事会 用于治疗自闭症谱系障碍及相关症状的方法

Also Published As

Publication number Publication date
WO2021081376A1 (en) 2021-04-29
CN114901270A (zh) 2022-08-12
EP4681714A2 (en) 2026-01-21
JP2022554090A (ja) 2022-12-28
EP4048249A4 (en) 2023-12-13
PT4048249T (pt) 2025-12-02
IL292367A (en) 2022-06-01
JP7766026B2 (ja) 2025-11-07
CA3158781A1 (en) 2021-04-29
US20220387396A1 (en) 2022-12-08
HRP20251489T1 (hr) 2026-01-02
MX2022004910A (es) 2022-08-18
DK4048249T3 (da) 2025-12-15
EP4048249B1 (en) 2025-09-03
FI4048249T3 (fi) 2025-12-05
AU2020370479A1 (en) 2022-04-28
EP4048249A1 (en) 2022-08-31
KR20220122602A (ko) 2022-09-02

Similar Documents

Publication Publication Date Title
CL2022001189A1 (es) Anticuerpos para cd40. (divisional de solicitud n° 2017003427)
EA202090510A1 (ru) Способ лечения бокового амиотрофического склероза придопидином
MX2021010265A (es) Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos.
MX2022001863A (es) Metodos para tratar los tumores del estroma gastrointestinal.
TN2019000210A1 (en) Antitumoral compounds
EP4302835A3 (en) Methods of treating ovarian cancer
MX2019004500A (es) Terapia de combinación para la inhibición de componente de complemeto (c3).
MX2021005075A (es) Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion.
IL286126A (en) Formulations for treating cluster symptoms associated with autism spectrum disorder
EP4327866A3 (en) Mirikizumab in the treatment of ulcerative colitis
PH12021550102A1 (en) Cardiosafe antidiabetic therapy
MX2025008168A (es) Métodos de tratamiento de los síntomas del trastorno del espectro autista.
MX2020008195A (es) Compuestos para el tratamiento del dolor.
NZ773183A (en) Mini-gde for the treatment of glycogen storage disease iii
WO2021041716A3 (en) Therapeutic editing to treat cardiomyopathy
MX2020003243A (es) Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada.
MX2023008839A (es) Composicion de liberacion tardia de linaclotida para uso en el tratamiento de trastornos gastrointestinales.
MX2020012292A (es) Compuestos para el tratamiento de cáncer de pancreas.
MX2020004074A (es) Producto de combinacion para el tratamiento de cancer.
ZA202105101B (en) Peptides for treatment and prevention of diabetes and associated disorders
MX2018001684A (es) Metodo de curacion de heridas.
GEAP202315793A (en) Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
ZA201908087B (en) Treatment for migraine
WO2015134603A3 (en) Methods for treating cancer
MY204088A (en) Method for treating non-compaction cardiomyopathy